This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (77)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Rachel M. Grossman, MD; Sylvie Chevret, MD, PhD; Johnny Abi-Rached, MD; Françoise Blanchet, MD; Louis Dubertret, MD

Arch Dermatol. 1996;132(6):623-629.

Abstract
Background and Design
Cyclosporine has proved to be highly effective in the treatment of psoriasis. However, cyclosporine is potentially toxic. Side effects include renal toxic effects, hypertension, and an increased risk of malignant neoplasm. The toxicity of cyclosporine is dose-related, yet the safe duration of treatment is undefined. We studied the hospital records of all patients with psoriasis treated with cyclosporine at Saint Louis Hospital, Paris, France, between January 1, 1987, and December 31, 1993. In total, 122 patients treated for 3 to 76 months were evaluated.

Results
The percentage of patients who discontinued treatment because of side effects rose from a mean±SD of 14%±2.4% at 12 months to 41%±6.7% at 48 months. An increase in serum creatinine levels to more than 30% above the baseline value occurred in 53 patients after a median treatment time of 23 months. Hypertension developed in 29 patients after a median treatment time of 53 months. Three initial patient characteristics—age older than 50 years (P=.04), initial diastolic pressure higher than 75 mm Hg (P=.05), and serum creatinine levels more than 100 µmol/L (1.1 mg/dL) (P=.02, log rank test)— predicted discontinuation of cyclosporine because of side effects.

Conclusions
The risk of cyclosporine-induced toxic effects increases with age of the patient and with preexisting hypertension or high serum creatinine levels. The data suggest that the incidence of side effects increases with time. Thus, cyclosporine is not an acceptable long-term monotherapy for psoriasis.

(Arch Dermatol. 1996;132:623-629)

Author Affiliations
From the Clinique des Maladies Cutanées (Drs Grossman, Abi-Rached, and Dubertret) and Département de Biostatistique et Information Médicale (Dr Chevret), Saint Louis Hospital, and the Service d'Explorations Fonctionnelles, Centre Hospitalier-Bichat et Claude Bernard (Dr Blanchet), Paris, France. Dr Grossman is now affiliated with Johnson & Johnson, Skillman, NJ.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses
Qureshi et al.
Arch Dermatol 2009;145:379-382.
ABSTRACT | FULL TEXT  

A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Lebwohl et al.
NEJM 2003;349:2004-2013.
ABSTRACT | FULL TEXT  

Immunomodulatory drugs for psoriasis
Boehncke
BMJ 2003;327:634-635.
FULL TEXT  

Long-term Effectiveness and Safety of Recombinant Human Interferon Gamma Therapy for Atopic Dermatitis Despite Unchanged Serum IgE Levels
Stevens et al.
Arch Dermatol 1998;134:799-804.
ABSTRACT | FULL TEXT  

Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy
Morison et al.
Arch Dermatol 1998;134:595-598.
ABSTRACT | FULL TEXT  

A 61-Year-Old Man With Psoriasis
Baughman
JAMA 1996;276:1421-1428.
ABSTRACT  

Long-term Use of Cyclosporine in Dermatology
Zachariae
Arch Dermatol 1996;132:692-694.
ABSTRACT